Catalog No.
DHK06401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3
Concentration
2.53 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NYJ7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SC0001-SCX, SC0002, CAS: 1613313-01-1
Clone ID
Rovalpituzumab
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study, PMID: 31506387
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study, PMID: 27932068
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate, PMID: 30232719
DLL3: an emerging target in small cell lung cancer, PMID: 31215500
Precision medicine for human cancers with Notch signaling dysregulation (Review), PMID: 31894255
Treatment advances in small cell lung cancer (SCLC), PMID: 28579387
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer, PMID: 33340277
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine, PMID: 31148500
Drugs in development for small cell lung cancer, PMID: 33209468
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer, PMID: 33257843
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer, PMID: 30894499
Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer, PMID: 27932065
Phototoxic drug reaction with the novel agent rovalpituzumab tesirine, PMID: 29319846
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC, PMID: 34425994
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer, PMID: 31446987
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study, PMID: 33823285
[Small Cell Lung Cancer], PMID: 29486510
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study, PMID: 33607312
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC, PMID: 33652156
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC, PMID: 34242790
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors, PMID: 34354225
Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer, PMID: 31981983
Advances in antibody therapeutics targeting small-cell lung cancer, PMID: 29790694
Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma, PMID: 30543588
Progress in the Management of Advanced Thoracic Malignancies in 2017, PMID: 29331646
Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma, PMID: 32372416
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments, PMID: 29116596
ADC Shows Effectiveness in SCLC, PMID: 26493959
Progress and challenges in the treatment of small cell lung cancer, PMID: 28456992
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer, PMID: 34329846
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy, PMID: 32543981
Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer, PMID: 28778960
Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies, PMID: 32267477
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges, PMID: 30968324
Current and future therapeutic approaches for the treatment of small cell lung cancer, PMID: 29544351
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?], PMID: 30100047
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload, PMID: 27882195
Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression, PMID: 33074129
Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer, PMID: 31412616
What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016, PMID: 28685608
Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer, PMID: 28487384
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702), PMID: 31068386
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer, PMID: 29290251
The clinical conundrum of managing relapsed small cell lung cancer, PMID: 30561759
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors, PMID: 31447005
Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview, PMID: 34107132
Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer, PMID: 31452726
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma, PMID: 30397180
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies, PMID: 29088717
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer, PMID: 29435295
For research use only. Not for human or drug use.
